



UNIVERSITY OF LEEDS

This is a repository copy of *Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/115014/>

Version: Supplemental Material

Article:

Meade, T, Manolios, N, Cumming, SR et al. (2 more authors) (2018) Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. *Arthritis Care & Research*, 70 (1). pp. 39-52. ISSN 2151-464X

<https://doi.org/10.1002/acr.23243>

(c) 2017, American College of Rheumatology. This is the peer reviewed version of the following article: 'Meade, T, Manolios, N, Cumming, SR et al (2017). Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. *Arthritis Care & Research*, 70 (1). pp. 39-52,' which has been published in final form at [<https://doi.org/10.1002/acr.23243>]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 4.

Characteristics of the 15 studies included in the Stage 4 and 5: populations, methodology and findings

Study ID Country Design	Sample Gender	Age (SD)	Education	Cognitive Domains Number of Tests	Cognitive Impairment (CI) % Cognitive Performance	Adjustments (A) Other Findings (OF) Limitations (L)	Modified Newcastle-Ottawa Quality Assessment Score (0-8)
23. Brown et al (2002) USA Cross-sectional	RA: 121 83% F	56.07 (12.74)	Mean (SD) not provided 100% 8 years 66% ≤ college	<ul style="list-style-type: none"> • Attention/ Concentration • Memory • Judgment/ Problem solving Tests: 6	CI: Not specified Cognitive Performance	A: Controlled for age and depression. OF: Age, depression and pain associated with CI. Age independently of depression and pain. L: No control group	5.0
29. Abeare et al, (2010) USA Cross-sectional	RA: 157 89.2% F	54 (11.44)	13.5 (no SD) range 1-21	<ul style="list-style-type: none"> • Attention • Memory Tests: 2	CI: Not specified Pain related to poorer cognitive function (Judgment)	A: Age, education, RA duration, ESR, fatigue & mood. OF: Positive affect moderates pain's impact on CF. L: No control group; limited cognitive assessment.	3.0
30. Shin et al (2013) USA Cross-sectional	RA: 115 63.5% F	58.6 (10.8)	15.11 (2.26)	<ul style="list-style-type: none"> • Attention/ Concentration • Verbal function • Visual-spatial organization • Memory • Judgment/ Problem 	CI: 31% on ≤4/16 tests Range: 8%-29% across tests CI based on 1 SD below the norm on 4/16	A: CF scores adjusted for age. CI lowest on semantic fluency (9%) and highest on visual special learning (29%). OF: 10 predictors explained 24%-34% of the variance in CI: key predictors: education, income, meds and CVD risk factors.	7.5

				solving	sub-tests.	L: No control group, pain, fatigue or sleep indicators.	
				Tests: 10 (16 sub-tests)			
31. Meade et al (2013) Australia 24 hour test-retest	RA: 35 59% F	61.20 (12.72)	64% ≤12 years	<ul style="list-style-type: none"> • Memory • Judgment/ Problem solving Tests: 2	CI: 0%	A: Controlled for age (test scores) and MTX dose. Some age and pain association with cognitive function OF: High and low MTX groups did not differ across demographic, clinical and mood indicators. Low MTX group performed marginally better than the high MTX group. L: Small, convenient sample, limited CF assessment.	5.5
32. Bartolini et al (2002) Italy Cross-sectional	RA: 30 90% F	55.6 (11.1)	5.78 (2.5)	<ul style="list-style-type: none"> • Attention/ Concentration • Verbal function • Visual-spatial organization • Memory • Judgment/ Problem solving Tests: 9	CI: 5% -71% (across 11 tests/sub-tests) Only 2/30 performed within normal range across all sub-tests Worst on Block Design (71%) and Rey Figure (50%)	A: Controlled for depression (excluded 17/47 based on BDI). OF: Cognitive performance related to disease indicators and age. MRI imaging: 35% to 85% had some abnormalities. L: No control group; lower education; no disease activity (quite high) control.	7.5
33. Appenzeller et al (2004)*	RA: 40 88% F Control: 40 95% F	37.2 (3.2) 35.9 (2.9)	RA: 7.2 (2.6) Control: 7.8 (1.3)	<ul style="list-style-type: none"> • Attention/ Concentration • Verbal function • Visual-spatial 	CI: RA: 30% CI: Control: 7.5%	A: No correlation between CI and RA duration, corticosteroid, neurological abnormalities, disability, depression, anxiety.	6.0

Brazil Cross-sectional				<ul style="list-style-type: none"> organization • Memory • Judgment/ Problem solving <p>Tests: Unclear</p>	<p>3/8 domains with ≥ 2 SD below the norm = moderate CI</p>	<p>OF: CI (Memory) linked to disease activity (6/12 with CI had cognitive problems & active RA).</p> <p>L: Lack of information of cognitive tests; no measure of pain or fatigue; small sample size.</p>	
34. Hamed et al (2012)* Egypt Cross-sectional	<p>RA: 55 100% F</p> <p>Control: 40</p>	<p>45.64 (10.91)</p> <p>Not provided</p>	<p>Not provided</p>	<ul style="list-style-type: none"> • Verbal function • Visual-spatial organization • Memory • Judgment/ Problem solving <p>Tests: 2 (11 sub-tests)</p>	<p>CI: unclear</p> <p>71% lower scores</p> <p>11% with indication of NSI</p> <p>9.35-13.2% brain abnormalities</p>	<p>A: Age, gender, SES, education matched. Age and illness duration controlled.</p> <p>OF: Found a link between biomarkers and CI; 7/55 RA had abnormal MRIs. These were not linked to disease activity or depression.</p> <p>L: Results based on correlations, no details on the score vs norms, only comparisons with Control.</p>	6.0
35. Petersen et al (2014)* Brazil Cross-sectional	<p>RA: 30 80% F</p> <p>Control: 15 75% F</p>	<p>50.60 (13.45)</p> <p>49.37 (15.23)</p>	<p>6.83 (3.80)</p> <p>8.37 (4.64)</p>	<ul style="list-style-type: none"> • Memory <p>Tests: 2</p>	<p>CI: Not specified</p>	<p>A: Controlled for age, mood and biomarker tests. RA performed poorer than Control.</p> <p>OF: RA and Control significantly different on biomarkers and predictors of CI. Case for 'inflammaging'.</p> <p>L: Not reported CI %.</p>	6.0
36. Tomasević-Todorovic et al (2011)* Serbia Cross-sectional	<p>RA: 60 88% F</p> <p>Control: 30 90% F</p>	<p>49.97 (7.56)</p> <p>48.30 (6.42)</p>	<p>RA: 92% ≤ 12 years</p> <p>Control: 77% ≤ 12 years</p>	<ul style="list-style-type: none"> • Memory <p>Tests: 1</p>	<p>CI: Not specified</p>	<p>A: Control group matched on gender, age and education but not controlled for significant difference in mood.</p> <p>OF: RA performed significantly</p>	4.5

						poorer on 4/5 cognitive sub-tasks compared to Control. Depression, anxiety and pain associated with CI in RA group. L: Not controlled for mood; not provided details on the CI results across five subscales.	
37. Akdogan et al (2013) Turkey Cross-sectional	RA: 28 FMS: 40 Control: 30 100% F	37.3 (6.0) 36.2 (7.3) 33.7 (8.0)	RA: 5-8 years: 27 (96.4%) 9-11 years: 1 (3.6%) FMS: 5-8 years: 34 (85%) 9-11 years: 6 (15%) Control: 5-8 years: 24 (80%) 9-11 years: 6 (20%)	• Attention Tests: 1	CI: Not specified Both RA and FMS had slower times but similar errors and corrections to Control	A: Age, education, risk factors (depression, anxiety, dizziness, sleep, fatigue). OF: Fatigue key predictor of CI. L: Small sample size; focus on FMS; only one domain/test.	4.0
38. Bilgici et al (2014) Turkey Cross-sectional	RA: 15 FMS: 16 Control: 15 100% F	38.1 (11.9) 36.8 (9.3) 35.3 (7.1)	RA: 7.3 (2.1) FMS: 8.4 (3.2) Control: 9.2 (5.6)	• Attention/ Concentration • Verbal function • Visual-spatial organization • Memory • Judgment/ Problem solving Tests: 13	CI: Not specified	A: Matched for age. Both FMS and RA performed worse than control. RA performed better than FMS but only significantly so on Judgment. OF: In RA pain correlated with Attention only. Fatigue and sleep problems did not correlate with any CF measures. L: Not quite matched on age and	4.5

						education (not significant differences). Not provided details re depression rates; no RA vs Control comparison; focused on FMS.	
39. de Melo et al (2012)* Brazil Cross-sectional	FMS: 13 RA: 13 SLE: 11 97% F (1:37 M:F)	53.3 (3.85) 55.07 (8.33) 37.54 (5.90)	FMS: 2.07 (0.75) RA: 1.84 (0.68) SLE: 2.27 (0.78)	<ul style="list-style-type: none"> • Verbal function • Visual-spatial organization • Memory • Judgment/ Problem solving Tests: 6	CI: Not specified	A: Not matched on age or education (SLE significantly younger). RA performed below norms on five sub-tests. OF: Each group performed below norms on some sub-tests. Significant age and education differences across sub-tests. L: Small sample not age or education matched, not separated for each group. Low education levels or a typographical error. Depression and clinical variables (pain, fatigue, disease activity) not measured.	4.5
40. Kozora et al (2001)* USA Cross-sectional	non-CNS-SLE: 15 RA: 15 Control: 15 100% F	39.7 (7.6) 38.7 (8.8) 37.7 (6.0)	13.5 (2.1) 13.2 (2.2) 13.5 (1.8)	<ul style="list-style-type: none"> • Attention/ Concentration • Verbal function • Visual-spatial organization • Memory • Judgment/ Problem solving Tests: 12	CI: Not specified DHEA-S significantly lower in RA vs Control	A: Similar on age and education. Used t-scores for domains. Controlled depression for comparisons. OF: BDI and one biomarker explained 36% out of 46% variance in CI (learning) while the other biomarker marginally contributed to CI (attention) (36% together with meds and depression). L: Small sample, mild disease activity.	7.0

<p>41. Yilmaz et al (2012)*</p> <p>Turkey Cross-sectional</p>	<p>Systemic Sclerosis: 31 96.7% F</p> <p>RA: 15 93.3% F</p> <p>Control: 20 95% F</p>	<p>Median (Range) 47(28-72)</p> <p>46 (33-61)</p> <p>47 (27-71)</p>	<p>Systemic Sclerosis: 8.8 (3.8)</p> <p>RA: 7.6 (6.6)</p> <p>Control: 10 (3.7)</p>	<ul style="list-style-type: none"> • Attention/ Concentration • Verbal function • Visual-spatial organization • Memory • Judgment/ Problem solving <p>Tests: 6</p>	<p>CI: Not specified</p>	<p>A: Groups matched on age, gender and education. Control performed better than both SS and RA on 5/6 tests. Suggest that Attention impairment leads to secondary memory problems.</p> <p>OF: RA performed better than SS. Education found to impact WCST test.</p> <p>L: Focus on SS, limited information on RA and small sample. No details re scores and norms.</p>	<p>7.0</p>
<p>42. Dick at al (2002)*</p> <p>Canada Cross-sectional</p>	<p>FMS: 20 90% F</p> <p>RA: 20 80% F</p> <p>MSD: 20 60% F</p> <p>Control: 20 35% F</p>	<p>48 (16.9)</p> <p>62.9 (10.9)</p> <p>52.3 (13.1)</p> <p>60.0 (12.4)</p>	<p>12.5 (2.7)</p> <p>*Inpatient population</p> <p>**FMS not age matched</p>	<ul style="list-style-type: none"> • Attention/ Concentration <p>Tests: 1</p>	<p>CI: Not specified for each clinical group</p> <p>Clinical Groups: CI: 60% on 1/4 tests CI: 38% on more than 1/4 tests</p>	<p>A: Control only age matched to RA. FMS significantly younger; no education match. 60% of the clinic groups had one subtest score in the clinically impaired range; 38% had more than one out of four subscales.</p> <p>OF: None of the demographical or clinical variables were significantly correlated with TEA test.</p> <p>L: Not age, gender (Control mostly male) or meds matched. No specified CI % for each group – all pooled together.</p>	<p>4.0</p>

* Included in effect size analyses (Table 5)